Streck Enters Distribution Agreement with Dow Biomedica
By Labmedica International staff writers
Posted on 31 Mar 2017
Image: Streck has entered into a distribution agreement with Dow Biomedica for its cell stabilization, molecular and flow cytometry products (Photo courtesy of iStock).
Streck, Inc., which develops and manufactures products for clinical and research laboratories, has entered into a distribution agreement for its cell stabilization, molecular and flow cytometry products with Dow Biomedica, a distributor of diagnostic products specializing in immunology, microbiology and QC materials.
Streck’s products for clinical and research laboratories include automated erythrocyte sedimentation rate instruments, and blood collection tubes that standardize methods for sample collection, stabilization and transportation during clinical research studies, drug discovery and diagnostic assay development. The company’s product lines also include flow cytometry, body fluids and urinalysis, as well as rapid diagnostic tools being developed for molecular diagnostics. Streck is also developing a library of diagnostics tools that will soon be available in Korea and the rest of the world.
“We are pleased to partner with a company that will allow Streck increased market penetration,” said Connie Ryan, President and CEO at Streck. “In addition, Dow Biomedica will be able to provide excellent local support to our Korean customers.”
“Dow Biomedica continuously pursues improving service for our customers, and our partnership with Streck will enable us to provide customers with the premium quality cell stabilization and flow cytometry products they need for their downstream applications,” said YG Shin, President and CEO of Dow Biomedica.